Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-02-22
1997-11-18
Dees, Jose G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514438, 514471, 514514, 514530, 514548, 514549, 514551, 514573, 514613, 514617, 514659, 514646, 514729, A61K 31135, A61K 3144, A61K 3138, A61K 3134
Patent
active
056888198
ABSTRACT:
The present invention provides cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compounds, which may be substituted in the 1-position with amino, amido, ether or ester groups, e.g., a 1-OH cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compound. The cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma. Moreover, the cyclopentane heptanoic, 2-(cycloalkyl or arylalkyl) compounds of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; smooth muscle relaxants with application in gastrointestinal disease, reproduction, fertility, incontinence, shock, etc.
REFERENCES:
patent: 4055602 (1977-10-01), Nelson
patent: 4171331 (1979-10-01), Biddlecom et al.
patent: 4183870 (1980-01-01), Caton et al.
patent: 4599353 (1986-07-01), Bito
patent: 4994274 (1991-02-01), Chan et al.
patent: 5034413 (1991-07-01), Chan et al.
patent: 5352708 (1994-10-01), Woodward et al.
patent: 5510383 (1996-04-01), Bishop et al.
patent: 5545665 (1996-08-01), Burk
patent: 5587391 (1996-12-01), Burk
patent: 5607978 (1997-03-01), Woodward et al.
Prostaglandins: vol. 13, No. 5, May 1977, Stoneham, MA, pp. 837-843, H.C. Arndt, "The Synthesis and Biological Activity of Prostaglandins Analogs Containing Spiroocyclic Rings".
Tetrahedron: Vo. 32, 1976, Oxford GB, pp. 2747-2752, P. De Clercqet al, "Cyclopentanones-VXI., Prostaglandin Synthesis Involving Catalytic Hydrogenation of 2,3-Dialkyl-4-Hydroxy-2-Cyclopentenones".
Bito, L.Z., "Prostaglandins and Related Compounds as Potential Ocular Therapeutic Agents", Biological Protection with Prostaglandins (Cohen, M.M., ed., Boc Raton, FL, CRC Press Inc., 1985, pp. 231-252.
Bito, L.Z., "Prostaglandins, Old Concepts and New Perspectives," Arch Oph., vol. 105, Aug. 1987 pp. 1036-1039.
Starr, M.S., "Further Studies on the Effect of Prostaglandin on Intraocular Pressure in the Rabbit", Exp. Eye Res., (1971) 170-177.
Nilsson, Siv F.E., et al, "PGF2a Increases Uveoscleral Outflow", ARVO Abstract, p. 284, Invest. Ophthalmol. Vis. Sci. 28 (suppl) (1987).
Bito, L.Z., "Prostaglandins, Other Eicosanoids, and Their Derivatives as Potential Antiglaucoma Agents", Applied Pharmacology in the Medical Treatment of Glaucoma, pp. 477-505, 1984.
Andrews Steven W.
Burk Robert M.
Garst Michael E.
Woodward David F.
Allergan
Baran Robert J.
Cebulak Mary C.
Dees Jos,e G.
Lambert Howard R.
LandOfFree
Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivativ does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivativ, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivativ will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1566010